Omalizumab is a humanised monoclonal antibody (RhuMab-E25) that binds selectively to circulating IgE, inhibiting its binding to the surface of mast cells and basophilic granulocytes. This prevents the release of pro-inflammatory mediators that produce an allergic response.
This targeted mechanism of action provides a novel therapeutic approach for the treatment of patients
with severe persistent, therapy-resistant allergic asthma. Omalizumab is administered subcutaneously in addition to other anti-asthma therapy. Until recently, the most important side effects are skin reactions at the site of administration and headache. Prospective data on additional long-term side effects are still being collected.
EPAR of omalizumab.